Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Nantkwest Inc CS (NK)

Nantkwest Inc CS (NK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,552,620
  • Shares Outstanding, K 109,345
  • Annual Sales, $ 110 K
  • Annual Income, $ -92,380 K
  • 60-Month Beta 2.38
  • Price/Sales 27,858.35
  • Price/Cash Flow N/A
  • Price/Book 30.17
Trade NK with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.39
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/24/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview

Details
  • Implied Volatility 0.00%
  • Historical Volatility 154.00%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.18
  • Number of Estimates 1
  • High Estimate -0.18
  • Low Estimate -0.18
  • Prior Year -0.16
  • Growth Rate Est. (year over year) -12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.15 +40.35%
on 03/05/21
45.42 -28.47%
on 02/22/21
+4.43 (+15.79%)
since 02/09/21
3-Month
10.00 +224.90%
on 12/10/20
45.42 -28.47%
on 02/22/21
+22.22 (+216.36%)
since 12/09/20
52-Week
2.52 +1,189.29%
on 04/03/20
45.42 -28.47%
on 02/22/21
+28.09 (+638.41%)
since 03/09/20

Most Recent Stories

More News
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?

Style Box ETF report for FYC

FYC : 70.42 (+0.04%)
IWO : 305.73 (+0.52%)
NK : 32.49 (+14.89%)
VBK : 285.12 (+0.97%)
SNBR : 121.98 (-0.20%)
EXPI : 37.86 (+1.45%)
3.1% Return Seen to Date on SmarTrend Nantkwest Inc Call (NK)

SmarTrend identified a Downtrend for Nantkwest Inc (NASDAQ:NK) on February 24th, 2021 at $33.52. In approximately 3 weeks, Nantkwest Inc has returned 3.07% as of today's recent price of $32.49.

NK : 32.49 (+14.89%)
ImmunityBio and NantKwest Complete Merger

ImmunityBio, Inc. and NantKwest, Inc. (NASDAQ: NK), today announced the completion of their previously announced 100% stock-for-stock merger. This follows the satisfaction of all customary closing conditions,...

NK : 32.49 (+14.89%)
IBRX : 17.26 (-4.48%)
Stockholders of NantKwest Approve Merger With ImmunityBio

NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that its stockholders approved by the required vote each of the proposals related to the...

NK : 32.49 (+14.89%)
ImmunityBio and NantKwest Begin Dosing Participants in Global Trials for Novel COVID-19 Vaccine; Subcutaneous Route in South Africa, Oral and Sublingual in the U.S.

ImmunityBio, Inc., a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced the first cohorts of their...

NK : 32.49 (+14.89%)
SHAREHOLDER ALERT: Barr Law Group Investigating NK, IQDNX, JELD, and MDXG; Shareholders are Encouraged to Contact the Firm

National law firm Barr Law Group is investigating the actions of the officers and board of directors of NantKwest, Inc., Infinity Q Diversified Alpha Fund, JELD-WEN Holding, Inc., and MiMedx Group, Inc....

NK : 32.49 (+14.89%)
JELD : 30.08 (+0.57%)
MDXG : 12.30 (+1.82%)
All Three Independent Proxy Advisory Firms - ISS, Glass Lewis and Egan-Jones - Recommend NantKwest Stockholders Vote "FOR" the Pending Merger With ImmunityBio

NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. ("ISS"),...

NK : 32.49 (+14.89%)
ImmunityBio Appoints John Brennan and Wesley Clark to Board of Directors

ImmunityBio, Inc., a privately-held immunotherapy company, today announced the appointment of John Brennan, former Central Intelligence Agency Director, and Wesley Clark, retired U.S. Army General, to...

NK : 32.49 (+14.89%)
Notable Tuesday Option Activity: NK, SAFM, PRPL

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in NantKwest Inc , where a total volume of 7,877 contracts has been traded thus far today,...

NK : 32.49 (+14.89%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - CTB, PBCT, HMSY, NK, SPWH

, /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

CTB : 57.26 (+0.40%)
PBCT : 17.91 (-0.78%)
HMSY : 36.97 (unch)
NK : 32.49 (+14.89%)
SPWH : 17.59 (+0.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

NantKwest, Inc. is a clinical-stage immunotherapy company. The Company's product candidates include aNK, haNK and taNK for the treatment of cancers, infectious and inflammatory diseases. It is focused on harnessing the power of the innate immune system by using the natural killer cell. NantKwest, Inc....

See More

Key Turning Points

3rd Resistance Point 37.26
2nd Resistance Point 35.20
1st Resistance Point 33.85
Last Price 32.49
1st Support Level 30.44
2nd Support Level 28.38
3rd Support Level 27.03

See More

52-Week High 45.42
Last Price 32.49
Fibonacci 61.8% 29.03
Fibonacci 50% 23.97
Fibonacci 38.2% 18.91
52-Week Low 2.52

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar